Provided by Tiger Trade Technology Pte. Ltd.

NYLI Merger Arbitrage ETF

36.73
+0.00400.01%
Post-market: 36.760.0259+0.07%19:30 EDT
Volume:10K
Turnover:353.04K
Market Cap:260.81M
PE:- -
High:36.82
Open:36.75
Low:36.71
Close:36.73
52wk High:37.19
52wk Low:35.49
Shares:7.10M
Float Shares:7.10M
Volume Ratio:0.32
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Hugo Boss Urges Shareholders to Reject Frasers Group's $2.2 Billion Takeover Bid

Deep News
·
Jul 09

Close the Loop Shareholders Back Capital Restructure and Board Appointment

TIPRANKS
·
Jul 09

Heartland merger timeline intact as Toi Foundation reopens TSB consultation

TIPRANKS
·
Jul 09

Global M&A Activity Soars This Year, Driven by Major AI Deals

Deep News
·
Jul 08

Getty Images Calls Off Its $3.7 Billion Acquisition of Shutterstock

Deep News
·
Jul 08

EasyJet Agrees in Principle to $6.7 Billion Takeover Bid from Castlelake

Deep News
·
Jul 07

BGR Energy Systems Doubles Authorised Share Capital After Shareholder Approval

TIPRANKS
·
Jul 07

EasyJet Accepts 7.3 Billion Dollar Takeover Bid from Castlelake, Signaling Potential Reshuffle of European Aviation

Deep News
·
Jul 06

EasyJet Soars on Castlelake's Revised $7.3 Billion Takeover Proposal

Deep News
·
Jul 06

Solasto Wins Approval for Share Consolidation Ahead of TSE Delisting

TIPRANKS
·
Jul 06

Genesis Minerals Makes Rival $3.9 Billion Bid to Acquire Vault Minerals

Deep News
·
Jul 06

EasyJet Agrees to Castlelake's £5.2 Billion Takeover Bid

Deep News
·
Jul 06

S.J.S. Enterprises gains shareholder approval on all AGM resolutions

TIPRANKS
·
Jul 04

Hardwyn India Boosts Authorised Share Capital After Shareholder Nod

TIPRANKS
·
Jul 04

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 15

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

GlobeNewswire
·
Apr 27

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

GlobeNewswire
·
Apr 01

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

GlobeNewswire
·
Mar 26